Related Experiment Video
Updated: Jul 22, 2025

A Method for Measuring RNA N6-methyladenosine Modifications in Cells and Tissues
Published on: December 5, 2016
N6-methyladenosine RNA modification: an emerging molecule in type 2 diabetes metabolism
Haocheng Zhang1,2,3, Yan Gu4, Qiaojian Gang1
1The Second School of Clinical Medicine, Lanzhou University, Lanzhou, Gansu, China.
Abstract:
Type 2 diabetes (T2D) is a metabolic disease with an increasing rate of incidence worldwide. Despite the considerable progress in the prevention and intervention, T2D and its complications cannot be reversed easily after diagnosis, thereby necessitating an in-depth investigation of the pathophysiology. In recent years, the role of epigenetics has been increasingly demonstrated in the disease, of which N6-methyladenosine (m6A) is one of the most common post-transcriptional modifications. Interestingly, patients with T2D show a low m6A abundance. Thus, a comprehensive analysis and understanding of this phenomenon would improve our understanding of the pathophysiology, as well as the search for new biomarkers and therapeutic approaches for T2D. In this review, we systematically introduced the metabolic roles of m6A modification in organs, the metabolic signaling pathways involved, and the effects of clinical drugs on T2D.
Insights
Type 2 diabetes (T2D) involves epigenetic changes, specifically reduced N6-methyladenosine (m6A) levels. Understanding m6A
Area of Science:
- Epigenetics
- Molecular Biology
- Metabolic Diseases
Background:
- Type 2 Diabetes (T2D) is a global metabolic epidemic.
- T2D pathophysiology and complications remain challenging to reverse post-diagnosis.
- Epigenetic modifications, particularly N6-methyladenosine (m6A), are emerging as key players in T2D.
Purpose of the Study:
- To comprehensively analyze the role of m6A modification in T2D pathophysiology.
- To explore the metabolic functions of m6A across different organs.
- To identify potential biomarkers and therapeutic targets for T2D based on m6A regulation.
Main Methods:
- Systematic review of existing literature on m6A modification in T2D.
- Analysis of metabolic signaling pathways influenced by m6A.
- Evaluation of the impact of clinical drugs on T2D-related m6A levels.
Main Results:
- Patients with T2D exhibit significantly lower m6A abundance.
- m6A plays crucial roles in metabolic regulation within various organs.
- Specific metabolic signaling pathways are modulated by m6A in the context of T2D.
Conclusions:
- Reduced m6A levels are a hallmark of T2D, impacting metabolic homeostasis.
- m6A modification represents a promising avenue for T2D biomarker discovery.
- Targeting m6A pathways could offer novel therapeutic strategies for T2D management.
Related Concept Videos
RNA Editing
Carbohydrate Metabolism
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
Diabetes Mellitus: Type 2 and Gestational
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Pathophysiology of Diabetes
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
RNA Stability

